Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

217.52 -3.90 (-1.76%)
Streaming Delayed Price Updated: 11:11 AM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
37 38 Next >
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes
The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm... 
Via Benzinga
What 24 Analyst Ratings Have To Say About Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings For Biogen
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter: 
Via Benzinga
Biogen: Q4 Earnings Insights
  Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biogen's Alzheimer's Struggles Continue; 'Minimal' Sales Expected This Year
Biogen's new Alzheimer's drug generated $1 million in fourth-quarter sales. 
Via Investor's Business Daily
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
The major indexes slashed weekly gains after Monday's follow-through day. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For February 4, 2022
Upgrades CBRE upgraded the previous rating for Penn National Gaming Inc (NASDAQ:PENN) from Hold to Buy. For the fourth quarter, Penn National Gaming had an EPS of $0.26,... 
Via Benzinga
Recap: Biogen Q4 Earnings
  Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 3, 2022
Companies Reporting Before The Bell • Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter. 
Via Benzinga
Biogen Snags $2.3 Billion In Samsung Biosimilars Deal; So, What's Next?
Analysts say the company could make an acquisition or another strategic move. 
Via Investor's Business Daily
10 Biggest Price Target Changes For Friday
JP Morgan boosted the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $4,350 to $4,500. Amazon shares jumped 11% to $3,081.07 in pre-market trading. 
Via Benzinga
Facebook FB plunges but Amazon AMZN surges: Earnings and Your Updated Price Levels
It seems like yesterday we were discussing the surge in Alphabet shares, and today we're focusing on big moves - currently in opposite directions - of Facebook and Amazon, all major market cap... 
Via Talk Markets
Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus
Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $ 
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Biogen Sells Biosimilar-Venture Stake To Samsung Biologics For $2.3B
Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on... 
Via Benzinga
Earnings Preview For Biogen
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will likely... 
Via Benzinga
World Markets News for Tuesday
Exxon is splitting into 3 with its new restructuring move: upstream; chemicals; and low-carbon. 
Via Talk Markets
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
Biogen Inc (NASDAQ: BIIB) has  
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
AskSlim Market Week - Friday, Jan. 28
Technical and cycle analysis, and market commentary. 
Via Talk Markets
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Monday
SVB Leerink cut Biogen Inc. (NASDAQ:BIIB) price ... 
Via Benzinga
14 Stocks in the Healthcare Sector
Here are 14 companies in the Healthcare Sector that have investment-grade credit ratings of BBB- or better, cash flow yield of 6% or better, future total return of at least 5%. 
Via Talk Markets
10 Biggest Price Target Changes For Tuesday
Keybanc raised J.B. Hunt Transport Services, Inc. (NASDAQ: 
Via Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
A rebound from Monday's lows faded, with the key indexes all down for the week. 
Via Investor's Business Daily
Two Curses Of The Current Year
The good news on inflation after this week's shocker is that December wholesale prices only rose 0.2%. 
Via Talk Markets
Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure
Denali Therapeutics is under pressure after the FDA put its study on hold. 
Via Investor's Business Daily
3 Biotech Stocks to Buy That Are Under Severe Pressure
The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom. 
Via InvestorPlace
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
37 38 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.